Cargando…
Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?
The most common complication in hemophilia A (HA) treatment, affecting 25% to 30% of patients with severe HA, is the development of alloimmune inhibitors that foreclose the ability of infused factor VIII (FVIII) to participate in coagulation. Inhibitors confer significant pathology on affected indiv...
Autores principales: | Pratt, Kathleen P., Gunasekera, Devi, Vir, Pooja, Tan, Siyuan, Pierce, Glenn F., Olsen, Cara, Butenas, Saulius, Mann, Kenneth G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471934/ https://www.ncbi.nlm.nih.gov/pubmed/36459498 http://dx.doi.org/10.1182/bloodadvances.2021004909 |
Ejemplares similares
-
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022) -
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022) -
Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII
por: Zhang, Yuan, et al.
Publicado: (2022) -
The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022) -
Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen
por: Simon, Barbara, et al.
Publicado: (2022)